Postconditioning with rosuvastatin reduces myocardial ischemia-reperfusion injury by inhibiting high mobility group box 1 protein expression

Du,Xianjin; Hu,Xiaorong; Wei,Jie

doi:10.3892/etm.2013.1362

Postconditioning with rosuvastatin reduces myocardial ischemia-reperfusion injury by inhibiting high mobility group box 1 protein expression

Authors:
- Xianjin Du
- Xiaorong Hu
- Jie Wei
View Affiliations

Affiliations: Department of Emergency, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: October 24, 2013 https://doi.org/10.3892/etm.2013.1362
Pages: 117-120

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High mobility group box 1 protein (HMGB1) plays an important role in myocardial ischemia-reperfusion (I/R) injury. Rosuvastatin (RS) preconditioning has been reported to reduce myocardial I/R injury. The aim of this study was to investigate whether postconditioning with RS is able to reduce myocardial I/R injury by inhibiting HMGB1 expression in rats. Anesthetized male rats were subjected to ischemia for 30 min and treated once with RS (10 mg/kg, i.v.) 5 min prior to reperfusion for 4 h. Lactate dehydrogenase (LDH), creatine kinase (CK) and superoxide dismutase (SOD) activities, malondialdehyde (MDA) levels and infarct size were measured. HMGB1 expression was assessed by immunoblotting. The results showed that RS postconditioning significantly decreased the infarct size and the activities of LDH and CK following 4 h reperfusion (all P<0.05). RS postconditioning also significantly inhibited the increase of MDA levels and the reduction of SOD activity (both P<0.05). RS postconditioning was able to significantly inhibit the HMGB1 expression induced by I/R. The present study suggested that postconditioning with RS reduces myocardial I/R injury, which may be associated with the inhibition of HMGB1 expression.

View Figures

View References

1	Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI
2	Bell CW, Jiang W, Reich CF III and Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol. 291:C1318–C1325. 2006. View Article : Google Scholar : PubMed/NCBI
3	Andrassy M, Volz HC, Igwe JC, et al: High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation. 117:3216–3226. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hu X, Jiang H, Bai Q, et al: Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin Chim Acta. 406:139–142. 2009. View Article : Google Scholar : PubMed/NCBI
5	Andrassy M, Volz HC, Riedle N, et al: HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J Intern Med. 270:245–253. 2011. View Article : Google Scholar : PubMed/NCBI
6	Hu X, Zhou W, Bai Q, et al: Increased serum high mobility group box 1 protein in patients with atrial fibrillation. Biomed Aging Pathol. 1:52–55. 2011. View Article : Google Scholar
7	Frangoginis NG, Smith CW and Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res. 53:31–47. 2002. View Article : Google Scholar
8	Hu X, Fu W and Jiang H: HMGB1: a potential therapeutic target for myocardial ischemia and reperfusion injury. Int J Cardiol. 155:4892012. View Article : Google Scholar : PubMed/NCBI
9	Jones SP, Gibson MF, Rimmer DM III, et al: Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol. 40:1172–1178. 2002. View Article : Google Scholar : PubMed/NCBI
10	Nangle MR, Cotter MA and Cameron NE: Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes. 52:2396–2402. 2003. View Article : Google Scholar
11	Susic D, Varagic J, Ahn J, et al: Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol. 42:1091–1097. 2003. View Article : Google Scholar : PubMed/NCBI
12	Weinberg EO, Scherrer-Crosbie M, Picard MH, et al: Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. Am J Physiol Heart Circ Physiol. 288:H1802–H1809. 2005. View Article : Google Scholar
13	Ke D, Fang J, Fan L, et al: Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury. Coron Artery Dis. 24:334–341. 2013. View Article : Google Scholar : PubMed/NCBI
14	Wang L, Zhang X, Liu L, et al: Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression. Neurosci Lett. 471:152–156. 2010. View Article : Google Scholar : PubMed/NCBI
15	Jin D, Wu Y, Zhao L, et al: Atorvastatin inhibits serum HMGB1 level in patients with hyperlipidemia. Exp Ther Med. 4:1124–1126. 2012.PubMed/NCBI
16	Hu X, Zhou X, He B, et al: Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol. 638:84–89. 2010. View Article : Google Scholar : PubMed/NCBI
17	McTaggart F, Buckett L, Davidson R, et al: Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 87:28B–32B. 2001. View Article : Google Scholar : PubMed/NCBI
18	Bell RM and Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 41:508–515. 2003. View Article : Google Scholar : PubMed/NCBI
19	Tang D, Shi Y, Kang R, et al: Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol. 81:741–747. 2007. View Article : Google Scholar : PubMed/NCBI
20	Tsung A, Klune JR, Zhang X, et al: HMGB1 release induced by liver ischemia involves Toll-like receptor 4 depedent reactive oxygen species production and calcium-mediated signaling. J Exp Med. 204:2913–2923. 2007. View Article : Google Scholar